Advertisement
UK markets close in 7 hours 2 minutes

  • FTSE 100

    7,851.25
    -114.28 (-1.43%)
     

  • FTSE 250

    19,391.45
    -307.44 (-1.56%)
     

  • AIM

    741.54
    -8.74 (-1.16%)
     

  • GBP/EUR

    1.1722
    +0.0012 (+0.10%)
     

  • GBP/USD

    1.2445
    -0.0002 (-0.01%)
     

  • Bitcoin GBP

    50,892.67
    -2,425.91 (-4.55%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CRUDE OIL

    85.26
    -0.15 (-0.18%)
     

  • GOLD FUTURES

    2,386.20
    +3.20 (+0.13%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • DAX

    17,785.70
    -240.88 (-1.34%)
     

  • CAC 40

    7,948.38
    -96.73 (-1.20%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

FDA approves GSK's Tanzeum to treat type 2 diabetes

Reuters - UK Focus

April 15 (Reuters) - The U.S. Food and Drug Administration approved GlaxoSmithKline Plc (Other OTC: GLAXF - news) 's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise.

Tanzeum will carry a warning on its label that tumors of the thyroid gland were observed in rodent studies with some drugs belonging to the same class. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website. (http://link.reuters.com/jyp58v)

The once-weekly drug, generically known as albiglutide, was approved last month in Europe, where it will be marketed as Eperzan.

Tanzeum belongs to the same class of injectable GLP (SES: E1:MC0.SI - news) -1 drugs as Victoza from Novo Nordisk (Other OTC: NONOF - news) and Byetta and Bydureon from AstraZeneca (NYSE: AZN - news) . (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)